Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus

BACKGROUND: Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch. METHODS: Sixty-one patients with type 2 diabetes swi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Endocrinol Metab (Seoul)
Huvudupphovsmän: Kim, Hyun Min, Lim, Jung Soo, Lee, Byung-Wan, Kang, Eun-Seok, Lee, Hyun Chul, Cha, Bong-Soo
Materialtyp: Artigo
Språk:Inglês
Publicerad: Korean Endocrine Society 2015
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384675/
https://ncbi.nlm.nih.gov/pubmed/25325279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3803/EnM.2015.30.1.84
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk